−5.3%
since Oct 1
The idea
I believe medicine by 2045 gets rewritten by two forces moving faster than the rest: GLP-1 metabolic drugs and AI-driven drug discovery, so this take leans into both with dedicated buckets while still spreading broadly across tools, gene editing cures, surgical care, and early detection. GLP-1 exposure is the two large players plus a smaller oral-pill challenger, and AI discovery spans several names rather than one bet. I keep cash on hand and cut every other bucket evenly to fund the tilt, and I would rethink it if either theme's momentum clearly stalls.
What it owns
- Equipment makers and lab suppliers earn revenue regardless of which drugs succeed, providing steady returns across all medical breakthroughs. · Thermo Fisher ScientificIt provides the lab equipment and services nearly every drugmaker depends on, earning from advances across all therapeutic areas., DanaherIt manufactures equipment used to produce biologic drugs including GLP-1s, connecting drug manufacturing to rising metabolic medicine demand., Agilent TechnologiesIt supplies instruments and testing equipment that labs use daily, providing steady support for expanding pharmaceutical and biotech research., IlluminaIts sequencing platform is the standard tool for reading DNA across genetic medicine and early detection, supporting multiple buckets in this take., West Pharmaceutical ServicesIt manufactures the stoppers and components inside injectable pens for GLP-1 drugs, earning from the same metabolic medicine wave as drug makers., 10x GenomicsIt supplies single-cell analysis tools that reveal biological detail at the finest scale, serving the frontier of research supporting all therapeutic advances.22%
- Artificial intelligence is becoming the standard tool for designing new drugs, and the companies supplying the chips, software and data infrastructure capture enduring value. · NVIDIAIt supplies the computer chips that power drug discovery efforts across the industry, making it the essential infrastructure for AI-designed medicines., Tempus AIIt converts real patient data into a foundation for AI-powered drug discovery and diagnostics, building infrastructure the industry increasingly needs., Recursion PharmaceuticalsIts entire pipeline consists of medicines discovered by artificial intelligence rather than conventional methods, betting that machines will find drugs humans would miss., SchrodingerIt sells physics-based simulation software that enables designers to engineer molecules on computers, a critical toll in the AI drug discovery shift., AbCellera BiologicsIt uses artificial intelligence to discover antibody drugs for partner companies, earning from the broader industry shift toward AI-enabled development.21%
- Gene editing and genetic medicine target disease at its root cause, offering the highest payoff if they deliver durable cures. · Vertex PharmaceuticalsIt converts genetic knowledge into approved cures for cystic fibrosis and sickle cell disease, proving genetic medicines can generate sustainable revenue., CRISPR TherapeuticsIt achieved the first FDA approval for a gene-editing cure, demonstrating that genetic medicine can move from concept to clinical reality., Regeneron PharmaceuticalsIt uses one of the world's largest genetic databases to identify drug targets, turning genomic insight into approved medicines., Beam TherapeuticsIt edits single DNA letters without cutting the strand, a gentler technique that could become standard for genetic cures as the field matures., ARK Genomic Revolution ETFIt holds a diversified portfolio of genomics companies, providing exposure to the long tail of gene-editing companies individually held here., Intellia TherapeuticsIt edits genes inside living patients rather than in laboratory dishes, a capability essential for genetic medicine to scale to common diseases.21%
- Obesity and metabolic disease represent the largest new pharmaceutical market in a generation, with demand still accelerating worldwide. · Eli LillyIt leads the GLP-1 market with Zepbound and Mounjaro, driving growth through both drug demand and manufacturing scale., Novo NordiskIt pioneered the GLP-1 category with Ozempic and Wegovy and remains one of the two largest makers in the metabolic medicine market., Viking TherapeuticsIt is developing oral pills for metabolic disease, challenging the injectable giants by offering convenience to patients seeking GLP-1 class benefits.13%
- Robotic surgery and continuous monitoring reshape how healthcare is delivered, independent of which drugs or treatments prevail. · Intuitive SurgicalIt dominates robotic surgery with a large installed base and growing procedure volumes that compound over time., DexComIts continuous glucose monitors are becoming standard for metabolic health management, and GLP-1 adoption is expanding the addressable patient population., InsuletIts tubeless insulin pumps gain share among people managing diabetes, addressing the care-delivery side of the metabolic disease opportunity.10%
- Blood tests that catch cancer at early stages represent a shift from invasive biopsies to simpler screening methods. · Guardant HealthIt detects cancer from blood samples instead of biopsies, enabling earlier intervention and ongoing monitoring., NateraIts tests identify cancer recurrence before imaging can detect it, already driving fast-growing revenue rather than relying on future adoption.7%
- Cash8%